Fig. 2
The effect of MOG1-125 conjugated PLGA nanoparticles + rapamycin complex. A: Difference between the routes of administration. MOG1-125 conjugated PLGA + rapamycin complex (10 mg/mL: Group A*) was administered intravenously, intraperitoneally, and subcutaneously, and the effects on clinical symptoms in mice were compared. Three of four mice (75%) with subcutaneous administration (STP SC: Group C*) showed re-exacerbation 1 week later. B: Optimal Dosage of MOG1-125 conjugated PLGA + rapamycin complex. Mice treated with diluted PLGA + rapamycin complex (1.0 mg/mL: Group D* and 0.1 mg/mL: Group E*) showed clinical signs similar to the negative control group*. C: The effect of PLGA nanoparticles without antigen. Not only MOG1-125 conjugated PLGA + rapamycin complex administration (Group A*) but also PLGA nanoparticles without antigen injection (Group F*) mitigated the clinical scores. D: serum MOG1-125 IgG concentration in each group. MOG-IgG level detected from mice serum decreased in administrations of MOG1-125 conjugated PLGA + rapamycin complex (10 mg/mL: Group A*), antigen alone PLGA nanoparticles (Group F*), PLGA nanoparticles without antigen (Group J*), and fingolimod as positive control*. The arrow indicates each group's intervention timing. *Grouping is shown in Table 1. FTY720 fingolimod, IP Intraperitoneal administration, IV Intravenous administration, PLGA Polylactic-co-glycolic acid, SC Subcutaneous administration, STP MOG1-125 conjugated PLGA + rapamycin complex